Fennec Pharmaceuticals (FENC) Downgraded by Zacks Investment Research to Hold

Fennec Pharmaceuticals stock has undergone multiple analysts rating changes in the recent past.  Fennec Pharmaceuticals Downgraded by Zacks Investment Research on 10/13/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Buy.

Shares of Fennec Pharmaceuticals traded down -$0.12 on Wednesday, reaching $9.36. 55616 shares of the stock traded hands, compared to its average volume of 41086. Shares of Fennec Pharmaceuticals were trading at $9.36 on Wednesday. The firm’s 50 day moving average is $8.20 and its 200 day moving average is $7.33.Fennec Pharmaceuticals has a 12 month low of $9.26 and a 12 month high of $9.83. While on yearly highs and lows, Fennec Pharmaceuticals’s today has traded high as $9.60 and has touched $9.26 on the downward trend. See More Analyst Rating at: RATING

Fennec Pharmaceuticals Earnings and What to expect: 

Fennec Pharmaceuticals last released its earnings data on August 10th, 2021. The reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.04. Fennec Pharmaceuticals has generated ($0.76) earnings per share over the last year (($0.70) diluted earnings per share). Earnings for Fennec Pharmaceuticals are expected to decrease in the coming year, from $0.57 to ($0.03) per share. Fennec Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, November 15th, 2021 based off prior year’s report dates.

Earnings for Fennec Pharmaceuticals are expected to decrease in the coming year, from $0.57 to ($0.03) per share. The P/E ratio of Fennec Pharmaceuticals is -13.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Fennec Pharmaceuticals is -13.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Fennec Pharmaceuticals has a P/B Ratio of 8.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Fennec Pharmaceuticals (FENC) Moving Average Technical Analysis

5 day Moving Average is $9.32 And 5 day price change is ()  with average volume for 5 day average is 34,160. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $9.15 and 20 day price change is $0.72 (8.33%) and average 20 day moving volume is 41,010. 50 day moving average is $8.20  and 50 day price change is $2.74 ( 41.39%)  and with average volume for 50 days is : 41,612. 200 day moving average is $7.33  and 200 day price change is $1.98 (26.83%)  and with average volume for 200 days is : 104,368.

Other owners latest trading in Fennec Pharmaceuticals :

  • On 9/17/2021 shares held by Virtu Financial LLC were 13,454 which equates to market value of $98K and appx 0.00% owners of Fennec Pharmaceuticals
  • On 9/3/2021 shares held by Parametric Portfolio Associates LLC were 22,435 which equates to market value of $0.16M and appx 0.00% owners of Fennec Pharmaceuticals
  • On 8/23/2021 shares held by Morgan Stanley were 43,430 which equates to market value of $0.32M and appx 0.00% owners of Fennec Pharmaceuticals
  • In total Institutional ownership equates to Institutional Ownership Percentage: 46.45% for Fennec Pharmaceuticals

See More Analyst Rating at: RATING